Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

oximately 5,000 to 8,000 Canadians.
Up to six months are needed to secure coverage for new medicines from the major private insurance companies in Canada and, on average, about 18 months are needed to secure reimbursement for all 10 provincial governments that reimburse the majority of medicines in Canada.
  • At the end of 2012, InterMune had concluded successful pricing and reimbursement discussions in nine European countries: Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway and Sweden.
  • InterMune today reiterated its current expectations regarding the on-going pricing and reimbursement processes for Esbriet in other European countries, processes over which InterMune has no control:
  • The UK – The appraisal by the National Institute for Health and Clinical Excellence (NICE) is expected to be completed in March of 2013.  If NICE provides a positive appraisal for Esbriet and the pricing and reimbursement conditions are acceptable, the company expects to launch Esbriet as soon as possible thereafter.
  • Italy – The company continues to expect to conclude the pricing and reimbursement process in the first quarter of 2013 and to launch Esbriet in Italy as soon as possible after the process is successfully concluded, assuming that acceptable pricing and reimbursement conditions are negotiated.  In Italy, up to three quarters are needed after national pricing and reimbursement is secured to address all regional reimbursement procedures before complete patient access to Esbriet is achieved.
  • Spain – InterMune currently expects to conclude pricing and reimbursement of Esbriet in Spain by mid-2013 and to launch as soon as possible after pricing and reimbursement is concluded, assuming that acceptable pricing and reimbursement conditions are negotiated.  In Spain, up to four quarters are needed after national reimbursement is secured to address all regional reimbursement proced
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... July 11, 2014 Research and Markets ... Technology Market - Global Industry Analysis, Size, Share, Growth, ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... acids (either DNA or RNA) into cells. This technology ... cancer cells and protein metabolism by affecting the nuclear ...
    (Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
    (Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
    (Date:7/10/2014)... Senior supply chain management executives from over ... challenges of “Reducing Cost, Lead Time, & Defects in ... Describing the partnership of the Bio Supply Management Alliance ... ( SCMI) of the University of San Diego ... Kroc Institute of Peace and Justice in San Diego, ...
    Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
    ... , Collaboration with Biomodels facilitates development ... Sept. 16 Avaxia Biologics, Inc., a biotechnology company developing oral ... that it has been awarded a Phase I SBIR grant from ... development of a novel antibody therapeutic for oral mucositis. , ...
    ... Sealers, cleaners, and ... , ... 16, 2009 - Tile Media Properties (TMP), best known for The Tile Doctor brand and ... The 10 year-old Atlanta-based company receives millions of unique visitors annually and is well-recognized as ...
    ... DIEGO, Sept. 16 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at the UBS Global Life Sciences Conference. The details ... September 22, 2009, Time: 2:30pm Eastern, ... Graham Cooper, Chief Financial Officer, , , ...
    Cached Biology Technology:Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3The Tile Doctor Launches Inaugural Product Line 2The Tile Doctor Launches Inaugural Product Line 3
    (Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
    (Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
    (Date:7/11/2014)... team of researchers, including scientists from the Max Planck ... reported a major step in understanding photosynthesis, the process ... the oxygen in its atmosphere and which is therefore ... , The researchers report the first direct visualization ... the step in which a specific protein complex, photosystem ...
    Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
    ... common condition affecting 12-20 percent of Americans age 65 ... heart attack and strokeand many with the disease may ... Interventional Radiology. For more than a decade, the ... Life, has helped identify this very serious and potentially ...
    ... , This press release is available in German . ... as defined by the EU Water Framework Directive is unlikely to ... a study in which data from the four largest rivers in ... analysed over ten years. The study was carried out by the ...
    ... Agriculture (USDA) aerial photography survey of 38,000 wildfire-burned acres ... first evidence that the invasive leafy spurge weed is ... Booth, a rangeland specialist with the Agricultural Research Service ... the survey using a technique he developed called Very ...
    Cached Biology News:Interventional radiologists: Learn about peripheral arterial disease and get moving 2Interventional radiologists: Learn about peripheral arterial disease and get moving 3Poor outlook for water quality in Germany 2Digital cameras open new view of America's West 2
    ... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
    ... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
    ... EIA Principle: Glutathion-S-transferases (GST) ... are involved in the detoxification processes. ... subgroups: Alpha, Mu, Pi, Teta and ... physiochemical, immunological, enzymatic and s Sample ...
    ... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... our comprehensive DNA/RNA Aptamer Microarray Service. ... RNA Aptamer Microarray contains greater than 1500 ...
    Biology Products: